Macquarie has downgraded Dr. Reddy’s Laboratories to a Neutral rating due to concerns over gRevlimid. This shift signals potential challenges ahead for the pharmaceutical company and could influence investor decisions.

Nauticus Robotics has announced a robust second quarter, driven by multiple new client projects that underscore its growing influence in the robotics sector. The company’s impressive performance highlights significant momentum within the industry.

Investor Gary Black anticipates that Tesla’s second-quarter deliveries will fall short of Wall Street estimates, suggesting that low expectations could make the release a ‘buy the news’ event. As attention shifts to Tesla’s Robotaxi ambitions in Austin, delivery numbers may become less significant to investors.

Time is running out to save hundreds on top-brand cordless vacuums. With up to 43% off Dyson, Samsung, Shark, and Roborock models, these expert-tested picks are the best deals before the EOFY ends.

In 2025, countries like the US, New Zealand, and Spain are pioneering new travel technologies, from AI-powered booking assistants to sustainable aviation. These innovations are enhancing convenience, personalization, and sustainability in the travel industry.

Elon Musk has announced that Tesla has delivered its first car fully autonomously from the factory to a customer’s home. While this could mark a significant leap in autonomous driving, questions remain about the system’s practicality and value.

A groundbreaking study from Dana-Farber Cancer Institute reveals that combining chemotherapy and immunotherapy before surgery can shrink aggressive stage III lung tumors, making surgery possible for patients previously deemed inoperable.

Cyngn’s stock soared by an astonishing 135% following the announcement of its partnership with Nvidia to showcase autonomous industrial vehicles at Automatica 2025. The collaboration marks a significant milestone in the autonomous vehicle industry.

Zymo Research made headlines at ASM Microbe 2025 with the unveiling of the MultiOmiX Workstation, a platform set to revolutionize microbiome workflows.

Liminatus Pharma is set to advance IBA101, a next-generation CD47 inhibitor designed to avoid the severe side effects that halted previous therapies, into human trials in the U.S. and Korea by early 2027. This innovative drug promises to redefine cancer immunotherapy by targeting tumors while sparing healthy cells, potentially offering new hope to patients.

The Global Mobile Scan Radiology Room Market is projected to grow significantly, expanding from USD 6.52 billion in 2025 to USD 10.73 billion by 2034. With a Compound Annual Growth Rate (CAGR) of 7.4%, the industry is poised for robust development driven by key growth factors.

Tesla’s recent launch of its robotaxi service in Austin has sent stock prices soaring, even as incidents caught on camera draw regulatory attention. Elon Musk is betting big on autonomous cabs to revitalize the company amid previous sales slumps.

Veho’s recent trial of RIVR’s wheel-legged delivery robots in Texas achieved a remarkable 95% success rate with minimal human intervention, according to CTO Fred Cook. This milestone signals a significant advancement in autonomous delivery technology.

Scientists in Pune are working diligently to isolate the COVID-19 sub-variants responsible for India’s recent spike in cases. This crucial step aims to assess the effectiveness of existing vaccines and determine whether new vaccines are needed, according to Dr. Naveen Kumar of the National Institute of Virology.

Elanco’s innovative treatment for canine allergies, Zenrelia, has received a positive opinion from European Union regulators. This milestone marks significant progress in addressing pet health concerns across Europe.

Jonathan Jones, a seventh grader from Minnesota, experienced the wonder of color for the first time after his principal, who is also colorblind, lent him special glasses. The emotional moment highlights the profound impact of empathy and innovation in changing lives.

Tesla’s long-awaited robotaxi service is tentatively scheduled to launch in Austin, Texas, on June 22, 2025, according to CEO Elon Musk. The company is placing a strong emphasis on safety, which may affect the actual timing of the rollout.

Arcutis Biotherapeutics has enrolled the first child in an open-label Phase II clinical trial to evaluate the efficacy of Zoryve (roflumilast) cream 0.05% for treating atopic dermatitis in infants. The INTEGUMENT-INFANT trial represents a significant step toward addressing a prevalent inflammatory skin condition among young children.

Elon Musk has revealed that Tesla is tentatively set to launch its robotaxi service in Austin, Texas, on June 22. This potential rollout marks a significant advancement in autonomous transportation for the company.

Facing invasive breast cancer, Kate Rouch, Chief Marketing Officer at OpenAI, turned to ChatGPT to navigate her treatment. Her journey illuminates the personal impact of AI technology in healthcare and offers a unique perspective from a leader in the tech industry.